ISSN: 1177-5475

Journal Home

Biologics: Targets and Therapy Q1 Unclaimed

Dove Medical Press Ltd. New Zealand

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Biologics: Targets and Therapy is a journal indexed in SJR in Immunology and Allergy and Oncology with an H index of 44. It is an CC BY-NC Journal with a Single blind Peer Review review system, and It has a price of 1762,2 €. The scope of the journal is focused on autoimmune diseases, cancer, biological agents. It has an SJR impact factor of 1,176 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,176.

Type: Journal

Type of Copyright: CC BY-NC

Languages: English

Open Access Policy: Open Access

Type of publications:

Publication frecuency: -

Categories: Gastroenterology (Q1) Oncology (Q1) Pharmacology (medical) (Q1) Rheumatology (Q1) Immunology and Allergy (Q2)

Price

1762,2 €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

1,176

SJR Impact factor

44

H Index

18

Total Docs (Last Year)

69

Total Docs (3 years)

1241

Total Refs

335

Total Cites (3 years)

69

Citable Docs (3 years)

4.21

Cites/Doc (2 years)

68.94

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Annals of the Rheumatic Diseases Q1
Journal of Experimental Medicine Q1
Journal of Cellular Immunotherapy Q1
Trends in Immunology Q1
Lancet Rheumatology, The Q1

Compare this journals

Aims and Scope

Autoimmune diseases Cancer Biological agents

Best articles by citations

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib

Pediatric ulcerative colitis: current treatment approaches including role of infliximab

Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines

Current neoadjuvant treatment options for HER2 positive breast cancer

Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress

Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus

Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency

Globular domain of adiponectin: promising target molecule for detection of atherosclerotic lesions

Palliative treatment of malignant ascites: profile of catumaxomab

Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?

Front line treatment of elderly multiple myeloma in the era of novel agents

SHOW MORE ARTICLES

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis

Biologic targeting in the treatment of inflammatory bowel diseases

Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency

A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis

Safety of etanercept in elderly subjects with rheumatoid arthritis

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy

Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID

Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis

Managing idiopathic short stature: role of somatropin (rDNA origin) for injection

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi"s sarcoma